Skip to main content


Latest articles

23-03-2021 | Diabetes | News | Article

STEP 4: Long-term treatment needed for full semaglutide benefit

People with obesity continue to lose weight if they remain on semaglutide 2.4 mg after an initial 20 weeks of treatment, but gradually regain it if they switch to placebo, show the STEP 4 findings.

22-03-2021 | Diabetes | News | Article

Hypoglycemia treatment advice needs modifying for low-glucose suspend systems

The amount of carbohydrate needed to treat mild or moderate hypoglycemia in people with type 1 diabetes using a predictive low-glucose suspend system may be considerably lower than what is currently recommended, report researchers.

19-03-2021 | Diabetes | News | Article

Antihyperglycemic medication CV benefits may be greater in Asian populations

Findings from a meta-analysis indicate that Asian people may derive greater cardiovascular benefit from SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists than their White counterparts.

18-03-2021 | Diabetes | News | Article

Insulin monotherapy ‘suboptimal’ for type 2 diabetes

Real-world study results suggest that people with type 2 diabetes treated with insulin monotherapy have worse clinical outcomes than those given combination treatment with insulin and other antidiabetic drugs.

17-03-2021 | Diabetes | News | Article

Dapagliflozin may have primary prevention role for HF, renal outcomes

Post-hoc analysis of the primary prevention subgroup of DECLARE-TIMI 58 suggests that treatment with dapagliflozin may reduce the risk for first heart failure and renal events.

16-03-2021 | Diabetes | News | Article

Frailty predictors identified in older people with type 2 diabetes

Older individuals with type 2 diabetes have a high risk for frailty, and risk predictors include poor glycemic control, depressive symptoms, and lifestyle factors, suggest findings from a Chinese cross-sectional study.

15-03-2021 | Diabetes | News | Article

Clinicians slow to address CV risk factors in type 2 diabetes

People with type 2 diabetes, particularly those diagnosed at a young age, can face an extended wait for medication to treat cardiovascular risk factors, even if they are in a high-risk category, research shows.

12-03-2021 | Diabetes | News | Article

Integrated management may improve type 1 diabetes pregnancy outcomes in resource-limited settings

Integrating a comprehensive management plan into the World Health Organization maternal care framework has the potential to improve pregnancy outcomes for women with type 1 diabetes, suggest findings from the CARNATION study.

11-03-2021 | Diabetes | News | Article

Psychosocial screening worthwhile for adolescents with type 1 diabetes

Routine psychosocial screening of adolescents with type 1 diabetes uncovers a sizable proportion who could benefit from additional support, say researchers.

10-03-2021 | Diabetes | News | Article

Two-step screening may be best for gestational diabetes

Single-step screening for gestational diabetes makes twice the number of diagnoses of the two-step approach without resulting in better outcomes for women and infants, shows the randomized ScreenR2GDM trial.

09-03-2021 | Diabetes | News | Article

Casual glucose level linked to CVD risk in absence of diabetes

A random blood glucose test in people without diabetes may provide a good indication of who has an increased risk for developing cardiovascular disease over the subsequent decade, a study suggests.

08-03-2021 | Diabetes | News | Article

Anti-IL-21, liraglutide combination may warrant further investigation for early type 1 diabetes

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

05-03-2021 | Diabetes | News | Article

Teplizumab offers extended preservation of beta-cell function

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

04-03-2021 | Diabetes | News | Article

Dapagliflozin HF benefits appear in less than a month

Dapagliflozin offers significant protection against worsening heart failure or cardiovascular death within 28 days of initiation, shows further analysis of DAPA-HF.

03-03-2021 | Diabetes | News | Article

STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes

The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.

02-03-2021 | Diabetes | News | Article

Signs of slowing diabetes incidence in higher-income countries

The incidence of diabetes in high- and middle-income countries may at last be stabilizing, or even in decline, say researchers.

01-03-2021 | Diabetes | News | Article

Sulfonylureas, insulin linked to increased hypoglycemia risk in older people with type 2 diabetes

Older individuals with type 2 diabetes and low glycated hemoglobin receiving treatment with a sulfonylurea or insulin have an increased risk for severe hypoglycemia, but there is no clear indication of an increased mortality risk, suggest UK study results.

26-02-2021 | Diabetes | News | Article

Hepatoselective glucokinase activator shows early promise in type 1 diabetes

Early findings suggest a novel molecule that selectively targets hepatic glucokinase may improve glucose control and reduce acute complication risk in people with type 1 diabetes.

25-02-2021 | Diabetes | News | Article

Community-based depression intervention cost-effective for people with type 2 diabetes

Findings from a modeling study suggest that community-based exercise and cognitive behavioral therapy interventions for depression in people with type 2 diabetes are cost-effective in the long-term.

24-02-2021 | Diabetes | News | Article

STEP 3: Semaglutide boosts weight loss during intensive behavioral therapy

Add-on treatment with subcutaneous semaglutide 2.4 mg produces a marked increase in weight loss for people without diabetes undertaking an intensive lifestyle intervention to combat obesity, report the STEP 3 investigators in JAMA.